Boundless Bio (BOLD) Competitors

$1.44 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.44 0.00 (0.00%)

As of 05/22/2026 04:04 PM Eastern

BOLD vs. AADI, TTRX, SPRB, PYRGF, and HYFT

Should you buy Boundless Bio stock or one of its competitors? MarketBeat compares Boundless Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Boundless Bio include Aadi Bioscience (AADI), Turn Therapeutics (TTRX), Spruce Biosciences (SPRB), PyroGenesis Canada (PYRGF), and MindWalk (HYFT).

How does Boundless Bio compare to Aadi Bioscience?

Boundless Bio (NASDAQ:BOLD) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Boundless Bio has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Boundless Bio's return on equity of -53.60% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-53.60%	-34.66%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Boundless Bio has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A
Aadi Bioscience	$25.07M	4.42	-$65.76M	-$2.35	N/A

Boundless Bio has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Boundless Bio presently has a consensus target price of $3.50, suggesting a potential upside of 143.06%. Given Boundless Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Boundless Bio is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aadi Bioscience had 1 more articles in the media than Boundless Bio. MarketBeat recorded 1 mentions for Aadi Bioscience and 0 mentions for Boundless Bio. Aadi Bioscience's average media sentiment score of 0.35 beat Boundless Bio's score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Boundless Bio	Neutral
Aadi Bioscience	Neutral

52.1% of Aadi Bioscience shares are owned by institutional investors. 23.1% of Boundless Bio shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Boundless Bio beats Aadi Bioscience on 8 of the 15 factors compared between the two stocks.

How does Boundless Bio compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Boundless Bio (NASDAQ:BOLD) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Turn Therapeutics' return on equity of 0.00% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Boundless Bio	N/A	-53.60%	-34.66%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A

Turn Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 55.95%. Boundless Bio has a consensus target price of $3.50, suggesting a potential upside of 143.06%. Given Boundless Bio's higher probable upside, analysts plainly believe Boundless Bio is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Turn Therapeutics had 2 more articles in the media than Boundless Bio. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Boundless Bio. Turn Therapeutics' average media sentiment score of 0.19 beat Boundless Bio's score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Turn Therapeutics	Neutral
Boundless Bio	Neutral

Summary

Turn Therapeutics beats Boundless Bio on 6 of the 8 factors compared between the two stocks.

How does Boundless Bio compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Boundless Bio (NASDAQ:BOLD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Boundless Bio's return on equity of -53.60% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Boundless Bio	N/A	-53.60%	-34.66%

91.7% of Spruce Biosciences shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 23.1% of Boundless Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Spruce Biosciences has higher revenue and earnings than Boundless Bio. Spruce Biosciences is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	28.61	-$38.97M	-$36.60	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A

In the previous week, Spruce Biosciences had 1 more articles in the media than Boundless Bio. MarketBeat recorded 1 mentions for Spruce Biosciences and 0 mentions for Boundless Bio. Spruce Biosciences' average media sentiment score of 0.00 equaled Boundless Bio'saverage media sentiment score.

Company	Overall Sentiment
Spruce Biosciences	Neutral
Boundless Bio	Neutral

Spruce Biosciences currently has a consensus target price of $186.60, suggesting a potential upside of 265.31%. Boundless Bio has a consensus target price of $3.50, suggesting a potential upside of 143.06%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Spruce Biosciences is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Spruce Biosciences has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market. Comparatively, Boundless Bio has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

Summary

Spruce Biosciences beats Boundless Bio on 8 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Boundless Bio (NASDAQ:BOLD) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Boundless Bio has a consensus price target of $3.50, indicating a potential upside of 143.06%. Given Boundless Bio's stronger consensus rating and higher possible upside, analysts clearly believe Boundless Bio is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.0% of PyroGenesis Canada shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PyroGenesis Canada has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Boundless Bio has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

In the previous week, PyroGenesis Canada had 1 more articles in the media than Boundless Bio. MarketBeat recorded 1 mentions for PyroGenesis Canada and 0 mentions for Boundless Bio. PyroGenesis Canada's average media sentiment score of 0.00 equaled Boundless Bio'saverage media sentiment score.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Boundless Bio	Neutral

Boundless Bio has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Boundless Bio	N/A	-53.60%	-34.66%

PyroGenesis Canada has higher revenue and earnings than Boundless Bio. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	4.63	-$21.12M	-$0.04	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A

Summary

PyroGenesis Canada and Boundless Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Boundless Bio compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Boundless Bio (NASDAQ:BOLD) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

MindWalk has higher revenue and earnings than Boundless Bio. MindWalk is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	4.49	-$21.69M	-$0.20	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.50	N/A

In the previous week, MindWalk had 3 more articles in the media than Boundless Bio. MarketBeat recorded 3 mentions for MindWalk and 0 mentions for Boundless Bio. MindWalk's average media sentiment score of 0.36 beat Boundless Bio's score of 0.00 indicating that MindWalk is being referred to more favorably in the media.

Company	Overall Sentiment
MindWalk	Neutral
Boundless Bio	Neutral

MindWalk has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Boundless Bio has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Boundless Bio has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Boundless Bio's return on equity of -53.60% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Boundless Bio	N/A	-53.60%	-34.66%

6.7% of MindWalk shares are owned by institutional investors. 6.8% of MindWalk shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MindWalk currently has a consensus target price of $5.00, suggesting a potential upside of 192.40%. Boundless Bio has a consensus target price of $3.50, suggesting a potential upside of 143.06%. Given MindWalk's stronger consensus rating and higher probable upside, research analysts clearly believe MindWalk is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Boundless Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MindWalk beats Boundless Bio on 11 of the 16 factors compared between the two stocks.

Get Boundless Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLD vs. The Competition

Export

Metric	Boundless Bio	PHARMACEUTICAL PREPARATIONS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$32.35M	$927.43M	$6.45B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	-0.58	1.46	21.22	25.65
Price / Sales	N/A	119.63	553.92	86.28
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	0.37	7.59	10.37	7.14
Net Income	-$58.20M	-$3.64M	$3.57B	$335.98M
7 Day Performance	1.41%	1.93%	6.01%	3.56%
1 Month Performance	-4.00%	76.78%	3.52%	2.54%
1 Year Performance	-8.05%	126.62%	34.13%	35.05%

Boundless Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLD Boundless Bio	2.6135 of 5 stars	$1.44 flat	$3.50 +143.1%	-8.0%	$32.35M	N/A	N/A	64
AADI Aadi Bioscience	N/A	$4.93 +25.8%	N/A	+155.1%	$121.76M	$25.07M	N/A	40	Gap Up High Trading Volume
TTRX Turn Therapeutics	3.0123 of 5 stars	$4.02 +0.2%	$8.00 +99.0%	N/A	$119.76M	N/A	N/A	2	Positive News Gap Down
SPRB Spruce Biosciences	2.1665 of 5 stars	$59.00 +2.5%	$186.60 +216.3%	+981.1%	$80.95M	N/A	N/A	20
PYRGF PyroGenesis Canada	N/A	$0.31 -7.1%	N/A	-37.4%	$64.12M	$9.14M	N/A	90	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLD) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boundless Bio (BOLD) Competitors

BOLD vs. AADI, TTRX, SPRB, PYRGF, and HYFT

How does Boundless Bio compare to Aadi Bioscience?

Summary

How does Boundless Bio compare to Turn Therapeutics?

Summary

How does Boundless Bio compare to Spruce Biosciences?

Summary

How does Boundless Bio compare to PyroGenesis Canada?

Summary

How does Boundless Bio compare to MindWalk?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boundless Bio (BOLD) Competitors

BOLD vs. AADI, TTRX, SPRB, PYRGF, and HYFT

How does Boundless Bio compare to Aadi Bioscience?

Is BOLD or AADI more profitable?

Which has better earnings & valuation, BOLD or AADI?

Which has more risk & volatility, BOLD or AADI?

Do analysts prefer BOLD or AADI?

Does the media refer more to BOLD or AADI?

Do institutionals and insiders have more ownership in BOLD or AADI?

Summary

How does Boundless Bio compare to Turn Therapeutics?

Is TTRX or BOLD more profitable?

Which has preferable earnings & valuation, TTRX or BOLD?

Do analysts recommend TTRX or BOLD?

Does the media prefer TTRX or BOLD?

Summary

How does Boundless Bio compare to Spruce Biosciences?

Is SPRB or BOLD more profitable?

Do insiders & institutionals have more ownership in SPRB or BOLD?

Which has stronger valuation & earnings, SPRB or BOLD?

Does the media prefer SPRB or BOLD?

Do analysts recommend SPRB or BOLD?

Which has more risk & volatility, SPRB or BOLD?

Summary

How does Boundless Bio compare to PyroGenesis Canada?

Do analysts recommend PYRGF or BOLD?

Do institutionals & insiders believe in PYRGF or BOLD?

Which has more risk and volatility, PYRGF or BOLD?

Does the media prefer PYRGF or BOLD?

Is PYRGF or BOLD more profitable?

Which has higher earnings & valuation, PYRGF or BOLD?

Summary

How does Boundless Bio compare to MindWalk?

Which has better earnings and valuation, HYFT or BOLD?

Does the media refer more to HYFT or BOLD?

Which has more volatility and risk, HYFT or BOLD?

Is HYFT or BOLD more profitable?

Do insiders & institutionals have more ownership in HYFT or BOLD?

Do analysts recommend HYFT or BOLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools